(Q37953583)

25 August 2017

title

Balancing clinical benefits of vigabatrin with its associated risk of vision loss (English)

1 reference

25 August 2017

0 references

J M Pellock

1

1 reference

25 August 2017

publication date

1 January 2011

1 reference

Acta neurologica Scandinavica. Supplementum

25 August 2017

published in

1 reference

25 August 2017

issue

192

1 reference

25 August 2017

page(s)

83-91

1 reference

Early identification of refractory epilepsy

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Sudden unexpected death in epilepsy: a review of incidence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Following catastrophic epilepsy patients from childhood to adulthood

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Long-term outcome of patients with West syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

A risk-benefit assessment of treatments for infantile spasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Mechanism of action of vigabatrin: correcting misperceptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Dose-Response Study of Vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Randomized trial of vigabatrin in patients with infantile spasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Vigabatrin for the treatment of infantile spasms: final report of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Effects of vigabatrin on partial seizures and cognitive function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Double-blind, placebo-controlled study of vigabatrin (gamma-vinyl GABA) in drug-resistant epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Vigabatrin in the treatment of epilepsy: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

21 January 2018

Vigabatrin: 2008 update

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Treatment of infantile spasms: results of a population-based study with vigabatrin as the first drug for spasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Vigabatrin therapy for refractory complex partial seizures: review of clinical trial experience in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Vigabatrin therapy for refractory complex partial seizures: review of major European trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Vigabatrin therapy for infantile spasms: review of major trials in Europe, Canada, and the United States; and recommendations for dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Visual field defects with vigabatrin: epidemiology and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Vigabatrin visual toxicity: evolution and dose dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

A controlled study of vigabatrin and visual abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

The effect on vision of associated treatments in patients taking vigabatrin: carbamazepine versus valproate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Visual fields at school-age in children treated with vigabatrin in infancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Electroretinogram changes in a pediatric population with epilepsy: is vigabatrin acting alone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Treatment of refractory complex partial seizures: role of vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Visual function is stable in patients who continue long-term vigabatrin therapy: implications for clinical decision making

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

The natural history of Vigabatrin associated visual field defects in patients electing to continue their medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Understanding and interpreting vision safety issues with vigabatrin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Primer on visual field testing, electroretinography, and other visual assessments for patients treated with vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

The potential for vigabatrin-induced intramyelinic edema in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Cerebral MRI abnormalities associated with vigabatrin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Transient brain magnetic resonance imaging hyperintensity in basal ganglia and brain stem of epileptic infants treated with vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Vigabatrin-associated reversible MRI signal changes in patients with infantile spasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Pathological evidence of vacuolar myelinopathy in a child following vigabatrin administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Non-vision adverse events with vigabatrin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Effects of vigabatrin on cognitive function and mood when used as add-on therapy in patients with intractable epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Influence of vigabatrin on cognitive performances and behaviour in patients with drug-resistant epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Psychiatric adverse events during vigabatrin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

When antiepileptic drugs aggravate epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Seizure-inducing effects of antiepileptic drugs: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Infantile spasms: a U.S. consensus report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Severe relapse of epilepsy after vigabatrin withdrawal: for how long should we treat symptomatic infantile spasms?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

Registry initiated to characterize vision loss associated with vigabatrin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

A pharmacogenetic exploration of vigabatrin-induced visual field constriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2011.01603.X

10.1111/J.1600-0404.2011.01603.X

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference